RxDoctor Payments Data

Kevin Kavanaugh, MD

Interventional Cardiology · Spokane, WANPI 1205889433

Payments from drug & device makers

$2,037in general payments, 2019–2025

Across 22 payments — averaging $92.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$2K
  • Boston Scientific$166
  • Abbott$97
  • Chiesi USA, Inc.$81
  • Johnson & Johnson$57
  • Cardiva Medical, Inc.$56
  • plus $80 from 5 others

What the payments were for

  • Speaking & faculty fees$1,50074%
  • Food & beverage$53726%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,037 in reported general payments places this provider in the 35th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$204,967
Medicare patients
1,625
Services billed
3,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban341$366,439
Repatha SureclickEvolocumab125$179,581
XareltoRivaroxaban110$149,179
EntrestoSacubitril/Valsartan45$80,527
Praluent PenAlirocumab62$64,449
Metoprolol Succinate262$4,686
Rosuvastatin Calcium231$4,134
Atorvastatin Calcium305$3,596
Potassium Chloride74$2,188
Losartan Potassium181$1,880
Carvedilol206$1,766
Metoprolol Tartrate180$1,534
Ezetimibe53$1,520
Isosorbide Mononitrate ErIsosorbide Mononitrate100$1,453
Lisinopril155$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$57$149,179110 claims
NovartisEntresto$14$80,52745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →